Nuformix PLC NXP002 Completion of Tolerability Studies (4681V)
10 August 2022 - 4:00PM
UK Regulatory
TIDMNFX
RNS Number : 4681V
Nuformix PLC
10 August 2022
10 August 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
NXP002 Successful Completion of Tolerability Studies
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that NXP002, a new form of
tranilast and a potential novel inhaled treatment for Idiopathic
Pulmonary Fibrosis ("IPF"), has successfully completed pre-clinical
tolerability studies for a new NXP002 formulation.
A s announced on 27 June 2022, the Company initiated further
pre-clinical studies as it continues to generate a robust data
package to support the progression of NXP002. Tolerability has been
demonstrated across a new range of doses, including higher doses
than previously given, delivered using an alternative method
designed to ensure that consistent and controlled inhalation
exposure is achieved.
Work has now commenced to explore how the new doses studied can
best optimise efficacy and confirm NXP002's positive
pharmacological profile towards the treatment of lung fibrosis and
inflammation via inhalation, before progression to a final step to
assess duration of action. Results will continue to be generated
throughout H2 2022 and further updates will be announced in due
course.
Dr Daniel Gooding, Executive Director of Nuformix, commented: "
The results from this first stage are exactly what we had hoped for
and bode well for the inhaled tolerability of NXP002, even at high
doses. We are pleased that we can now progress to robustly
investigate NXP002's efficacy as we continue to build a
pre-clinical data package to support the further progression of the
Company's lead programme. I look forward to providing further
updates to the market when appropriate."
Enquiries:
Nuformix plc
Dr Daniel Gooding, Executive Director Via IFC Advisory
Dr Julian Gilbert, Non-executive
Chairman
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
About Fibrosis
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Idiopathic Pulmonary Fibrosis is classified as a rare
disease and presents a global commercial market that is forecast to
grow to $5bn by 2025. Sales of standard-of-care therapies OFEV and
Esbriet achieved $2.58bn and $1.04bn respectively in 2021.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSSIFMUEESEDA
(END) Dow Jones Newswires
August 10, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024